Figure 5. Recombinant TM lectin-like domain (rTMD1) suppressed RANKL-induced bone resorption and reduced ovariectomy-induced bone loss.

(A) RANKL-induced TRAP activity in RAW264.7 cells was measured after rTMD1 treatment for 4 days. (B) Results of RANKL-induced bone resorption in RAW264.7 cells after treatment with various doses of rTMD1. (C) Western blotting analysis of extracellular HMGB1 from TM^LeD/LeD mice BMMs in response to rTMD1 treatment. CM, conditioned medium; Lys, cell lysates. (D) After OVX, an intraperitoneal injection of rTMD1 (1 mg/kg) was performed every 3 days until sacrificed. Bone loss in tibia was detected by μCT scanning in wild-type mice with or without rTMD1 treatment, within 4 weeks of ovariectomy. (E) Quantified BV/TV of (D). n = 5. (F) Quantitative results of BV/TV in ovariectomized wild-type mice treated with various doses of intraperitoneal rTMD1 injection (0.5 mg/kg, 1 mg/kg, 3 mg/kg). n = 5. BV, trabecular bone volume; TV, total bone volume. (G) H&E staining of the tibia after 4 weeks of ovariectomy. bar = 50 μm. Student’s t-test (A); One-way ANOVA (B), (F); Two-way ANOVA (E). *P < 0.05, **P < 0.01, ***P < 0.001.